Inj, cipaglucosidase, 5 mg
Products billed under this code include Pombiliti.
Payment limit per 5 MG, by effective quarter, 3Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Pombiliti.
Payment limit per 5 MG, by effective quarter, 3Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Pombiliti | Amicus Therapeutics US, LLC | 71904-0200-01 | 21 | $2,026.311 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $96.491 | +$0.189 | 5 MG | Inj, cipaglucosidase, 5 mg | v1, posted September 17, 2026 |
| 3Q26 | $96.302 | +$3.904 | 5 MG | Inj, cipaglucosidase, 5 mg | v1, posted September 15, 2026 |
| 2Q26 | $92.398 | +$1.195 | 5 MG | Inj, cipaglucosidase, 5 mg | v1, posted September 15, 2026 |
| 1Q26 | $91.203 | −$0.01 | 5 MG | Inj, cipaglucosidase, 5 mg | v1, posted September 15, 2026 |
| 4Q25 | $91.213 | +$1.416 | 5 MG | Inj, cipaglucosidase, 5 mg | v1, posted September 8, 2026 |
| 3Q25 | $89.797 | −$0.049 | 5 MG | Inj, cipaglucosidase, 5 mg | v1, posted March 10, 2026 |
| 2Q25 | $89.846 | +$0.469 | 5 MG | Inj, cipaglucosidase, 5 mg | v1, posted March 10, 2026 |
| 1Q25 | $89.377 | +$1.322 | 5 MG | Inj, cipaglucosidase, 5 mg | v1, posted December 19, 2025 |
| 4Q24 | $88.055 | −$0.086 | 5 MG | Inj, cipaglucosidase, 5 mg | v1, posted June 11, 2025 |
| 3Q24 | $88.141 | – | 5 MG | Inj, cipaglucosidase, 5 mg | v1, posted June 11, 2025 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.